Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate

被引：0
|
作者：
Cosman, F. [1 ]
Wermers, R. A. [2 ]
Recknor, C. [3 ]
Mauck, K. F. [2 ]
Xie, L. [4 ]
Glass, E. V. [4 ]
Krege, J. H. [4 ]
机构：
[1] Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY USA
[2] Mayo Clin, Rochester, MN 55905 USA
[3] United Osteoporosis Ctr, Gainesville, FL 32601 USA
[4] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
CALCIFIED TISSUE INTERNATIONAL | 2008年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [31] EFFECT OF TERIPARATIDE IN CHINESE AND CAUCASIAN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: BRIDGING FINDINGS ON EFFICACY
    Li, M.
    Gurbuz, S.
    Chen, Y.
    Zhang, B.
    Li, Y. J.
    Chen, Y.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S216 - S216
  • [32] Effects of teriparatide on quality of life in postmenopausal women with osteoporosis
    Rosa, Jan
    Kasalicky, Petr
    Mala, Ivana
    BONE, 2008, 42 : S85 - S86
  • [33] Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis
    Johnson, Bruce E.
    ANNALS OF INTERNAL MEDICINE, 2012, 157 (06)
  • [34] The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis
    Hartz, Martin C.
    Johannessen, Fabian B.
    Harslof, Torben
    Langdahl, Bente L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [35] Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis
    Meng Kong
    Changtong Gao
    Xiaona Luan
    Cuiying Fan
    Meng Hao
    Canghai Jin
    Jiangning Zhao
    Hongyan Li
    Jindong Zhao
    Jian Luan
    Yong Lin
    Qiang Li
    BMC Musculoskeletal Disorders, 25
  • [36] Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
    Le, Quang A.
    Hay, Joel W.
    Becker, Russell
    Wang, Yamei
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 134 - 143
  • [37] Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis
    Krege, J. H.
    Wan, X.
    BONE, 2012, 50 (01) : 161 - 164
  • [38] THE EFFECT OF TERIPARATIDE ON BONE MATERIAL PROPERTIES IS NOT DIFFERENT IN POSTMENOPAUSAL WOMEN WHO WERE PREVIOUSLY TREATMENT-NAIVE OR TREATED WITH ALENDRONATE
    Buchinger, Birgit
    Gamsjaeger, Sonja
    Dobnig, Harald
    Stepan, Jan
    Burr, David
    Petto, Helmut
    Pavo, Imre
    Klaushofer, Klaus
    Paschalis, Eleftherios
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 286 - 286
  • [39] Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
    Adami, S.
    Martin, J. San
    Munoz-Torres, M.
    Econs, M. J.
    Xie, L.
    Dalsky, G. P.
    McClung, M.
    Felsenberg, D.
    Brown, J. P.
    Brandi, M. L.
    Sipos, A.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (01) : 87 - 94
  • [40] Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis
    Kocjan, Tomaz
    Rajic, Antonela Sabati
    Janez, Andrej
    Vidmar, Gaj
    Orehek, Nina
    Marc, Janja
    Ostanek, Barbara
    ENDOCRINE PRACTICE, 2021, 27 (09) : 941 - 947
12345